In addition, we observed that emricasan induces robust antigen-specific serum IgG1 and BALF IgA without significantly inducing antigen-specific serum IgE, which is responsible for type 1 allergic hypersensitivity [55]; this may explain the reduced incidence of post-injection side effects. The gene discussed is CD79A; the disease is hypersensitivity.